Reducing Risk in Early Cell and Gene Therapy Manufacturing in the Face of Capacity Crunch

Presented by: Ravi Samavedam, Chief Innovation Officer (CINO), Azzur Group With more than 400 registered gene therapy clinical trials worldwide and a compound annual growth rate of more than 25% since 2015, there is no doubting the impact of cell and gene therapy (CGT) innovation on the market. In fact, the industry is expected to […]

To access this post, you must purchase MEMBER PLUS +.

You must log in to view this content.

Presented by: Ravi Samavedam, Chief Innovation Officer (CINO), Azzur Group With more than 400 registered gene therapy clinical trials worldwide and a compound annual growth rate of more than 25% since 2015, there is no doubting the impact of cell and gene therapy (CGT) innovation on the market. In fact, the industry is expected to […]
To access this post, you must purchase MEMBER PLUS +.

Become a Member to View this Content

Please provide your information below

Recommended for you

More resources

Be first to know about our next events!

Register to receive updates

31 E Kings Highway
2nd Floor Haddonfield, NJ 08033

  • Email: info@kenx.org
  • Phone: 858 649 3251
  • Email: info@kenx.org
  • Phone: 858 649 3251
Facebook-f Linkedin-in